Crossmark

Fragile X-associated tremor/ataxia syndrome — features, mechanisms and management

Crossref DOI link: https://doi.org/10.1038/nrneurol.2016.82

Published Online: 2016-06-24

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hagerman, Randi J.

Hagerman, Paul
License Information

Text and Data Mining valid from 2016-06-24
More Information

Article History

First Online: 24 June 2016

Competing interests

: R.H. has received funding from Alcobra, Neuren, Novartis, Roche and Seaside Therapeutics to carry out treatment studies in fragile X syndrome, autism and Down syndrome. R.H. has also consulted with Novartis, Roche/Genentech and Zynerba regarding treatment studies in fragile X syndrome. P.H. is an uncompensated collaborator with Pacific Biosciences and Roche regarding new <i>FMR1</i> sequencing strategies; he holds patents for <i>FMR1</i> genotyping and protein tests.